SINGAPORE, Aug. 4, 2025 /PRNewswire/ -- Tikva Allocell (Tikva), a biotechnology company developing off-the-shelf CAR-T cell therapies for solid tumors, today announced that its Founder and CEO, Dr. Ivan Horak will join a keynote panel at the Asian Pharma and Biotech Project, Program and Portfolio Management Conference, being held in Singapore, August 5-6, 2025.

"I look forward to exploring how innovation, investment, and strategic thinking are shaping the region's future in drug development, including advancing next generation therapies for cancer," said Dr. Horak. "Headquartered in Singapore, Tikva is led by a seasoned cell therapy development team with extensive experience in designing and developing 'off-the-shelf' T cell therapies utilizing Allogeneic Epstein-Barr Virus (EBV)-Specific T cells (ALLO EBVST). We look forward to discussing how Tikva is leading this next generation of CAR-T technology, and the role Singapore will play in the future of this key sector."

The panel is titled "The Evolving Pharma and Biotech Landscape in Asia, Accelerating Drug Development Through Innovation, Investment, and Strategic Growth." Panelists will discuss the state of drug development projects in Asia including key opportunities and challenges in clinical trials, R&D, and commercialization, as well as the role of incubators, government agencies, and venture funding are playing to supporting early-stage innovation and accelerate drug development. The dialogue will also elaborate on key regulatory shifts, AI, and emerging technologies and how these factors are transforming clinical development and portfolio management in Asia.

Details of the presentation are as follows:

During the conference, Dr. Horak will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent achievements, and anticipated milestones.

About Tikva Allocell
Tikva Allocell Pte Ltd is a biotechnology company developing a pipeline of off-the-shelf CAR-T cell therapies for solid tumors.  Tikva's CAR-T products are built from the company's proprietary ALLO EBVST (Epstein-Barr Virus) platform, which utilizes highly specific, second-generation, allogeneic Virus-Specific T cells (VSTs) to increase cell persistence and reduce graft-versus-host diseases (GvHD) without the need for genetic editing.  Tikva's lead development program, TAVST01, is designed to target B7-H3 positive solid tumors, including lung, breast, prostate and pancreatic cancers. Preclinical research involving TAVST01 has demonstrated its ability to address both tumor cells and the immunosuppressive tumor micro-environment with a potentially lymphodepletion-free safety profile that enables multiple dosing or combination therapies.  For more information on Tikva, please visit www.tikvaallocell.com.

Contacts

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com

View original content:https://www.prnewswire.com/news-releases/tikva-allocell-to-participate-in-keynote-panel-discussion-at-asian-pharma-and-biotech-project-program-and-portfolio-management-conference-302519921.html

SOURCE Tikva Allocell